Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation featuring preclinical data on OP-1250, a complete estrogen receptor antagonist and selective ER degrader. This data will be showcased at the 1st JCA-AACR Precision Cancer Medicine International Conference, occurring virtually from September 10-12, 2021. The presentation, titled "Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development," will be available on-demand on the conference website. The company aims to advance targeted therapies for women’s cancers.

SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation of new preclinical data on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers, at the 1^st JCA-AACR Precision Cancer Medicine International Conference being held virtually from September 10-12, 2021 (U.S.) and September 11-12 (Japan).

A virtual e-poster presentation titled, "Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development," along with a pre-recorded audio narration will be available on-demand on the conference website.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “expect,” “intend,” “will,” “may,” “goal,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the development of OP-1250, including timelines related to data presentation, trial initiation and advancement, and enrollment, as well as the sufficiency of our financial resources. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that Olema’s ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer and other risks and uncertainties affecting Olema, as well as those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 to be filed on August 10, 2021 and future filings and reports that Olema makes from time to time with the United States Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com

FAQ

What is the significance of Olema Pharmaceuticals' OP-1250 presentation at the conference?

Olema Pharmaceuticals' presentation highlights new preclinical data on OP-1250 as a promising treatment option for metastatic breast cancer at the JCA-AACR conference.

When is the 1st JCA-AACR Precision Cancer Medicine International Conference taking place?

The conference is scheduled from September 10-12, 2021, for U.S. participants and September 11-12 for attendees in Japan.

What is OP-1250 being developed for?

OP-1250 is being developed as a treatment for metastatic breast cancer and other women's cancers.

What is the role of Olema Pharmaceuticals in women's cancer therapies?

Olema Pharmaceuticals focuses on the discovery, development, and commercialization of targeted therapies specifically for women's cancers.

Is OP-1250 currently undergoing clinical trials?

Yes, OP-1250 is being evaluated in an ongoing Phase 1/2 clinical trial for patients with recurrent, locally advanced, or metastatic ER-positive breast cancer.